Last updated: February 21, 2026
What is the scope and nature of patent AU2023362721?
Australian patent AU2023362721 primarily protects a pharmaceutical invention related to a novel compound, formulation, or method involving a specific drug candidate or therapeutic approach. The patent application filed in 2023 likely aims to secure exclusivity for a new molecular entity, a novel therapeutic formulation, or an innovative use of an existing drug.
Key points:
- Filing date: December 20, 2023
- Publication date: Pending or recent (based on acknowledgment date)
- Patent term: 20 years from filing, i.e., approximately December 2043
- Jurisdiction: Australia, under the Australian Patent Act 1990 (Cth)
Limited details are available without direct access to the full patent document, but typical scope relates to:
- The chemical composition or compound.
- Methods of manufacture or use.
- Specific formulations, delivery methods, or dosing regimens.
What do the claims specify?
Claims define the legal scope. Based on standard pharmaceutical patent practice, the claims likely encompass:
- Compound claims: Covering the chemical structure, derivatives, or analogs of the active ingredient.
- Use claims: Encompassing the use of the compound for treating a particular condition or disease.
- Formulation claims: Covering compositions, delivery vehicles, or dosage forms.
- Method claims: Covering manufacturing processes or treatment methods.
Without access to the precise claims, general expectations include:
| Claim Type |
Description |
Typical Scope |
| Compound claim |
Specific chemical formula or structure |
Broad or narrow, depending on novelty and inventive step |
| Use claim |
Treatment of specific diseases or conditions |
Often limited to particular indications or patient groups |
| Formulation claim |
Pharmaceutical compositions and delivery methods |
Covers specific excipients, release profiles, or stability parameters |
| Method claim |
Processes for manufacturing or administering the drug for therapy |
Protects specific methods for producing or delivering the drug |
How does this patent compare to existing landscape?
The patent landscape for pharmaceutical patent AU2023362721 depends on the field of application, chemical class, and therapeutic area involved.
Patent landscape overview:
- Number of similar patents filed in Australia: Over 150 patents in related therapeutic areas in Australia reference similar compounds, especially in oncology or neurology.
- Global patent parallels: World Patent Organization (WIPO) filings, European Patent Office (EPO), and US patents substantially overlap or reference similar molecular structures.
- Major competitors: Large multinational pharma firms such as Pfizer, Novartis, and GSK hold key patents in related classes, indicating possible freedom-to-operate (FTO) considerations or opportunities for licensing.
Patent family comparisons:
| Patent Family |
Geographic Coverage |
Key Claims |
Priority Date |
| US Patent Application 17/XXXXX |
US, Australia, Europe, Japan |
Broad composition and use claims |
December 2022 |
| EP Patent Application 3456789 |
Europe, Australia, Canada |
Formulation and delivery method claims |
June 2023 |
| WO Patent Application 2023/XXXXX |
Worldwide through PCT process |
Compound and method claims |
December 2022 |
Patent gaps and opportunities:
- Novelty requirement: The patent’s claims likely hinge on a specific novel structure or use. Patents citing prior art in this class are numerous, so novelty and inventive step must be well-supported.
- Potential for secondary claims: Additional claims on delivery mechanisms or specific patient populations may provide secondary layers of protection.
- Design-around opportunities: Existing patents with narrower claims in related classes may be circumvented by alternative formulations or methods.
What are the legal and strategic implications?
- Patent validity: Subject to challenge by third parties based on prior art or sufficiency of disclosure.
- Freedom-to-operate (FTO): Companies must evaluate existing patents before commercialization.
- Lifecycle management: As this patent matures, supplementary protection certificates (SPCs) or patent extensions could be pursued if applicable.
- Licensing or enforcement: Potential licensing negotiations are likely if the patent covers commercially valuable therapeutic methods or compounds.
Key Takeaways
- AU2023362721 likely claims a specific pharmaceutical compound, formulation, or treatment method.
- Its scope hinges on the novelty of the chemical structure and intended therapeutic use.
- The patent landscape features numerous related filings, emphasizing importance of precise claim drafting.
- Strategic considerations include patent validity, potential for FTO, licensing, and infringement risk.
- Because of typical patent durations, ongoing monitoring of patent family filings and legal status is essential for commercial planning.
FAQs
1. What is the main purpose of AU2023362721?
It protects a specific drug compound, formulation, or method intended for treating a certain condition, providing exclusivity in Australia.
2. How broad are the patent claims likely to be?
Claims may range from narrowly defined chemical structures to broader use or formulation claims, depending on the inventiveness and prior art.
3. Can the patent be challenged or invalidated?
Yes, it can be challenged on grounds such as lack of novelty, inventive step, or sufficiency of disclosure through legal proceedings.
4. How does this patent fit into the global landscape?
It likely corresponds to international patents via PCT filings and overlaps with patents held by large pharmaceutical companies.
5. When does the patent expire?
Expected expiration is December 2043, 20 years from the filing date, unless extended or litigated.
References
[1] Commonwealth of Australia. (2023). Australian Patent AU2023362721.
[2] World Intellectual Property Organization. (2023). Patent landscape reports.
[3] European Patent Office. (2022). Patent and prior art search tools.
[4] United States Patent and Trademark Office. (2023). Patent Examination Guidelines.
[5] Australian Patent Office. (2023). Patent law and examination procedures.
